Mucormycosis treatment to be covered under Aarogyasri

The State government has issued an order for including the ‘Post-COVID Mucormycosis Management’ procedure under Aarogyasri considering it an epidemic disease due to the rising number of cases among patients after COVID recovery with uncontrolled diabetes, prolonged usage of high dose steroids and immunosuppressants.

As per the G.O., the new procedure for the disease includes a 14-day stay of the patient in the hospital, where the disease is diagnosed and treated. As per the treatment protocol, patients are given IV antibiotics, IV fluids, Liposomal Amphotericin B or oral Posaconazole for two to three weeks based on clinical evaluation.

Meanwhile, Health, Medical and Family Welfare Principal Secretary Anil Kumar Singhal said that the State had placed an order for over 15,000 vials of medicine with three companies to treat mucormycosis in addition to the 1,650 allocated by the Centre.

In a press conference on Wednesday, he said that it would cost up to ₹3 lakh per person to treat mucormycosis and the government had included the disease under the Aarogyasri scheme.

He said information on black fungus was still being collected. The Health Department has notified 17 government and teaching hospitals across the State to treat the disease.



Crime Today News is an online news website that conveys the data you have to know. We will likely transform information into data and data into understanding.

Related Posts